Moderna (MRNA) Tops Q2 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
August 5, 2021 6:29 AM EDTModerna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose
Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2
Dosing started in Phase 1 studies for quadrivalent seasonal flu vaccine candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders (mRNA-6231)
Moderna has mRNA candidates in clinical development across five therapeutic areas: infectious disease, cardiovascular, oncology, rare disease and autoimmune disorders
Q2 total revenue of $4.4... More
